Published in J Biopharm Stat on January 01, 2005
Bridging clinical investigators and statisticians: writing the statistical methodology for a research proposal. J Investig Med (2009) 0.91
Power and sample size calculations for evaluating mediation effects in longitudinal studies. Stat Methods Med Res (2012) 0.80
A comparison of power analysis methods for evaluating effects of a predictor on slopes in longitudinal designs with missing data. Stat Methods Med Res (2012) 0.78
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol (2003) 3.58
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
Retracted Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. Am J Respir Crit Care Med (2012) 2.39
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. J Thorac Oncol (2015) 2.17
A distribution-free test of constant mean in linear mixed effects models. Stat Med (2008) 1.97
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91
Nonparametric inference on median residual life function. Biometrics (2007) 1.90
Accuracy of ROPtool vs individual examiners in assessing retinal vascular tortuosity. Arch Ophthalmol (2007) 1.81
Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol (2003) 1.70
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg (2003) 1.58
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Mutational hotspots in the mitochondrial genome of lung cancer. Biochem Biophys Res Commun (2011) 1.54
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica (2011) 1.48
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44
A retrospective analysis of facial fracture etiologies. Ann Plast Surg (2008) 1.33
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg (2003) 1.28
Gradient lasso for Cox proportional hazards model. Bioinformatics (2009) 1.21
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer (2012) 1.21
Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res (2008) 1.19
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest (2004) 1.10
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther (2010) 1.08
Appropriate design of prospective studies. J Clin Oncol (2012) 1.05
Statistical considerations for analysis of microarray experiments. Clin Transl Sci (2011) 1.00
A permutation-based multiple testing method for time-course microarray experiments. BMC Bioinformatics (2009) 1.00
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. Genet Epidemiol (2013) 1.00
A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med (2003) 0.99
Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study. J Clin Oncol (2003) 0.98
Rank tests for clustered survival data when dependent subunits are randomized. Stat Med (2006) 0.98
permGPU: Using graphics processing units in RNA microarray association studies. BMC Bioinformatics (2010) 0.96
Designing phase II studies in cancer with time-to-event endpoints. Clin Trials (2008) 0.95
A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer. Ann Surg (2016) 0.92
Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine (Baltimore) (2016) 0.92
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther (2010) 0.89
Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Pancreas (2015) 0.88
Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test. Stat Med (2013) 0.87
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs (2013) 0.86
Power and sample size calculations for SNP association studies with censored time-to-event outcomes. Genet Epidemiol (2012) 0.86
Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci (2007) 0.85
Physician self-referral of lumbar spine MRI with comparative analysis of negative study rates as a marker of utilization appropriateness. AJR Am J Roentgenol (2012) 0.84
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer (2013) 0.83
Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. Cancer Genet Cytogenet (2004) 0.82
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Res Treat (2015) 0.82
A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. Int J Cancer (2014) 0.82
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma (2013) 0.81
A SAS macro for a clustered logrank test. Comput Methods Programs Biomed (2011) 0.79
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma (2014) 0.79
Prediction of a time-to-event trait using genome wide SNP data. BMC Bioinformatics (2013) 0.79
SNP selection in genome-wide association studies via penalized support vector machine with MAX test. Comput Math Methods Med (2013) 0.79
Multiple testing for gene sets from microarray experiments. BMC Bioinformatics (2011) 0.79
Sample size calculation for simulation-based multiple-testing procedures. J Biopharm Stat (2005) 0.78
Journal Club: Shoulder MRI utilization: relationship of physician MRI equipment ownership to negative study frequency. AJR Am J Roentgenol (2013) 0.78
A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer. Ann Surg (2016) 0.77
Bayesian analysis of paired survival data using a bivariate exponential distribution. Lifetime Data Anal (2007) 0.77
Genetic profiling to predict recurrence of early cervical cancer. Gynecol Oncol (2013) 0.77
Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism. Medicine (Baltimore) (2016) 0.75
Quantification of Aortic Valve Calcifications Detected During Lung Cancer-Screening CT Helps Stratify Subjects Necessitating Echocardiography for Aortic Stenosis Diagnosis. Medicine (Baltimore) (2016) 0.75
Does the interval of screening endoscopy affect survival in gastric cancer patients?: A cross-sectional study. Medicine (Baltimore) (2016) 0.75
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
Optimal estimation for regression models on τ-year survival probability. J Biopharm Stat (2015) 0.75
Robust test method for time-course microarray experiments. BMC Bioinformatics (2010) 0.75
A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol (2005) 0.75
Predictive Model for Neoplastic Potential of Gallbladder Polyp. J Clin Gastroenterol (2017) 0.75
Application of an adjusted chi2 statistic to site-specific data in observational dental studies. J Clin Periodontol (2002) 0.75
Journal of Biopharmaceutical Statistics. From the editors. J Biopharm Stat (2009) 0.75
Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism. Medicine (Baltimore) (2016) 0.75
A copula approach for detecting prognostic genes associated with survival outcome in microarray studies. Biometrics (2007) 0.75
Designs for randomized phase II clinical trials with two treatment arms. Stat Med (2013) 0.75
Screening Magnetic Resonance Imaging-Based Prediction Model for Assessing Immediate Therapeutic Response to Magnetic Resonance Imaging-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids. Invest Radiol (2016) 0.75